Home Access Health
This article was originally published in The Gray Sheet
Executive SummaryPremarket approval application for the company's Hepatitis C Check at-home telemedicine counseling and testing service, submitted in December, will receive an expedited and streamlined review from FDA, the firm states Feb. 19. The agency referenced the current Hepatitis C lookback program as one of the primary reasons for the move, according to Home Access ("The Gray Sheet" Dec. 21, In Brief)
You may also be interested in...
South Korea’s HLB has begun a new growth phase by taking over US-based clinical stage biotech firm Immunomic Therapeutics. Through the acquisition, it is poised to add new pipeline assets including a Phase II vaccine therapy for glioblastoma and proprietary lysosomal targeting technology.
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.
Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.